Aetion pockets $36.4 mln Series B
New York City-based Aetion, a provider of real-world analytics and evidence for biopharma customers and payers, has raised $36.4 million in Series B funding. New Enterprise Associates led the round with participation from Amgen Ventures, Flare Capital Partners, Lakestar and Oxeon Ventures. In addition to the funding, Mohamad Makhzoumi of NEA will join Aetion's board of directors.
11 April 2018•1 min read
